Cargando…

Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report

Immune checkpoint inhibitors (ICIs) have greatly transformed the treatment and improved the prognosis for patients with non-small cell lung cancer (NSCLC) without driver gene alterations. However, the effects of ICI combination therapy in ROS1 fusion-positive NSCLC remains unclear. Herein, we presen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Ningning, Huang, Siyuan, Li, Linlin, Guo, Qianqian, Geng, Di, Zhang, Huixian, Guo, Sanxing, Li, Xingya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500430/ https://www.ncbi.nlm.nih.gov/pubmed/36160430 http://dx.doi.org/10.3389/fphar.2022.898623

Ejemplares similares

Corrigendum: Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report
por: Yan, Ningning, et al.
Publicado: (2023)

A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer
por: Geng, Di, et al.
Publicado: (2022)

Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients
por: Zhang, Huixian, et al.
Publicado: (2023)

Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report
por: Yan, Ningning, et al.
Publicado: (2023)

Corrigendum: Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report
por: Yan, Ningning, et al.
Publicado: (2023)

BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective
por: Yan, Ningning, et al.
Publicado: (2022)

Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and literature review
por: Li, Linlin, et al.
Publicado: (2023)

LINC01089 functions as a ceRNA for miR-152-3p to inhibit non‐small lung cancer progression through regulating PTEN
por: Zhang, Huixian, et al.
Publicado: (2021)

Retraction Note: LINC01089 functions as a ceRNA for miR-152-3p to inhibit non‐small lung cancer progression through regulating PTEN
por: Zhang, Huixian, et al.
Publicado: (2022)

Nasopharyngeal papillary adenocarcinoma harboring a fusion of ROS1 with GOPC: A case report
por: Wang, Jinjing, et al.
Publicado: (2021)

Successful targeting of the NRG1 fusion reveals durable response to afatinib in lung adenocarcinoma: a case report
por: Wu, Xiaokang, et al.
Publicado: (2021)

Case report: complete remission with crizotinib in ROS1 fusion-positive sinonasal mucosal melanoma
por: Cao, Jun, et al.
Publicado: (2022)

Elevation of tumor mutation burden in ROS1-fusion lung adenocarcinoma resistant to crizotinib: A case report
por: Yang, Tao, et al.
Publicado: (2018)

ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib
por: Xu, Shuguang, et al.
Publicado: (2019)

Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report
por: Nie, Xin, et al.
Publicado: (2023)

Durable response to crizotinib in an advanced lung adenocarcinoma patient harboring rare CD47-MET fusion: a case report
por: Liu, Junfang, et al.
Publicado: (2022)

Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report
por: Shu, Yun, et al.
Publicado: (2020)

The taxane-based chemotherapy triplet is superior to the doublet in one to nine node-positive but not node-negative triple-negative breast cancer: results from a retrospective analysis
por: Guo, Sanxing, et al.
Publicado: (2020)

Identification of a Rare BAIAP2-ROS1 Fusion and Clinical Benefit of Crizotinib in the Treatment of Advanced Lung Adenocarcinoma: A Case Report
por: Lin, YunYu, et al.
Publicado: (2022)

STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report
por: Zhang, Linlin, et al.
Publicado: (2022)

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review
por: Zhu, You‐cai, et al.
Publicado: (2017)

Schimke Immuno-osseous Dysplasia: A Case Report
por: Babaei, Amir Hossein, et al.
Publicado: (2019)

A case of adenocarcinoma of the rete testis with durable response to cisplatin‐based chemotherapy
por: Owa, Shunsuke, et al.
Publicado: (2021)

Crizotinib, an Effective Agent in ROS1-Rearranged Adenocarcinoma of Lungs: A Case Report
por: Joshua, Julie Mariam, et al.
Publicado: (2018)

Schimke immuno-osseous dysplasia. A case report in Colombia
por: Orozco, Rafael Adrián Pacheco, et al.
Publicado: (2023)

Durable response to osimertinib in an advanced lung adenocarcinoma patient with an uncommon EGFR T854A mutation: A case report
por: Zhao, Nan, et al.
Publicado: (2022)

Identification of a novel RMST-ALK rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: A case report
por: Li, Hui, et al.
Publicado: (2022)

Atrial fibrillation was changed into sinus bradycardia in a ROS1-positive advanced lung adenocarcinoma patient who achieved durable response to Crizotinib: A case report and literature review
por: Liu, Lan, et al.
Publicado: (2017)

Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report
por: Zhou, Huamiao, et al.
Publicado: (2021)

Case Report: Short-Term Response to First-Line Crizotinib Monotherapy in a Metastatic Lung Adenocarcinoma Patient Harboring a Novel TPR-ROS1 Fusion
por: Wei, Shuli, et al.
Publicado: (2022)

Editorial Comment to A case of adenocarcinoma of the rete testis with durable response to cisplatin‐based chemotherapy
por: Yuasa, Takeshi
Publicado: (2021)

Case Report: Detection of Double ROS1 Translocations, SDC4-ROS1 and ROS1-GK, in a Lung Adenocarcinoma Patient and Response to Crizotinib
por: Xu, Long, et al.
Publicado: (2021)

Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report
por: Xia, Huanling, et al.
Publicado: (2022)

Case Report: Gastric-Type Endocervical Adenocarcinoma Mimicking Submucosal Myoma Under Hysteroscopy
por: Wang, Jiao, et al.
Publicado: (2022)

Pralsetinib treatment for multiple RET fusions in lung adenocarcinoma: a case report
por: Cao, Xiangming, et al.
Publicado: (2022)

Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
por: Chen, An-guo, et al.
Publicado: (2022)

Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review
por: Zhao, Lingling, et al.
Publicado: (2021)

Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report
por: Leyrat, Brice, et al.
Publicado: (2021)

LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report
por: Yang, Yanlong, et al.
Publicado: (2022)

Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab
por: Chahoud, Jad, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_215t5792ntt4500fcd8roit0t9